Proteasome Inhibition Induces Both Antioxidant and Hb F Responses in Sickle Cell Disease Via the Nrf2 Pathway

References

• Nur E, Biemond BJ, Otten H-MB, et al. Oxidative stress in sickle cell disease: Pathophysiology and potential implications for disease management. Am J Hematol. 2011;86(6):484–489
   PubMed Web of Science ®Google Scholar
• Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine and new research directions. Am J Hematol. 2009;84(9):618–625
   PubMedGoogle Scholar
• Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–2031
   PubMed Web of Science ®Google Scholar
• Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J. 2005;19(8):989–991
   PubMed Web of Science ®Google Scholar
• Kaul DK, Liu XD, Choong S, et al. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol. 2004;287(1):H293–H301
   PubMed Web of Science ®Google Scholar
• Hur W, Gray NS. Small molecule modulators of antioxidant response pathway. Curr Opin Chem Biol. 2011;15(1):162–173
   PubMed Web of Science ®Google Scholar
• Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol. 2011;85(4):241–272
   PubMed Web of Science ®Google Scholar
• Villeneuve NF, Lau A, Zhang DD. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: An insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal. 2010;13(11):1699–1712
   PubMed Web of Science ®Google Scholar
• Macari ER, Lowrey CH. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. Blood. 2011;117(22):5987–5997
   PubMed Web of Science ®Google Scholar
• Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19–27
   PubMed Web of Science ®Google Scholar
• Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–1644
   PubMed Web of Science ®Google Scholar
• Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11–16
   PubMed Web of Science ®Google Scholar
• Risso A, Fabbro D, Damante G, Antonutto G. Expression of fetal hemoglobin in adult humans exposed to high altitude hypoxia. Blood Cells Molec Dis. 2012;48(3):147–153
   PubMedGoogle Scholar
• Yang YM, Pace B, Kitchens D, et al. BFU-E colony growth in response to hydroxyurea: Correlation between in vitro and in vivo fetal hemoglobin induction. Am J Hematol. 1997;56(4):252–258
   PubMedGoogle Scholar
• Ho JA, Pickens CV, Gamscik MP, et al. In vitro induction of fetal hemoglobin in human erythroid progenitor cells. Exp Hematol. 2003;31(7):586–591
   PubMedGoogle Scholar
• Reece DE, Sullivan D, Lonial S, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 2011;67(1):57–67
   PubMed Web of Science ®Google Scholar
• Sekhar KR, Soltanninassab SR, Borrelli MJ, et al. Inhibition of the 26S proteasome induces expression of GLCLC, the catalytic subunit for gamma-glutamylcysteine synthetase. Biochem Biophys Res Commun. 2000;270(1):311–317
   PubMedGoogle Scholar
• Stewart D, Killeen E, Naquin R, et al. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J Biol Chem. 2003;278(4):2396–2402
   PubMedGoogle Scholar
• Xia L, Pan J, Yao L, McEver RP. A proteasome inhibitor, an antioxidant or a salicylate, but not a glucocorticoid blocks constitutive and cytokine-inducible expression of P-selectin in human endothelial cells. Blood. 1998;91(5):1625–1632
   PubMedGoogle Scholar
• Lalu MM, Xu H, Sankaralingam S, Davidge ST. Proteasome inhibition decreases inflammation in human endothelial cells exposed to liposaccharide. J Cardiovasc Pharmacol. 2012;60(4):381–389
   PubMedGoogle Scholar
• Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: Prospects for new therapies for the β-globin disorders. Blood. 2012;120(15):2945–2953
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Nathan DG. Reversing the hemoglobin switch. N Engl J Med. 2010;363(23):2258–2260
   PubMed Web of Science ®Google Scholar
• Forget BG. Progress in understanding the hemoglobin switch. N Engl J Med. 2011;365(9):852–854
   PubMedGoogle Scholar
• Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985–4991
   PubMed Web of Science ®Google Scholar
• Lebensburger JD, Pestina TI, Ware RE, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010;95(9):1599–1603
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Lu Z-H, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Blood. 1997;89(3):1078–1088
   PubMed Web of Science ®Google Scholar
• Chandra J. Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies. Antioxid Redox Signal. 2009;11(5):1123–1137
   PubMedGoogle Scholar
• Mullard A. Next-generation proteasome blockers promise safer cancer therapy. Nat Med. 2012;18(1):7 . doi:10.1038/nm0112-7a
   PubMedGoogle Scholar
• Dick LR, Fleming PE. Building on bortezomib: Second generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today. 2010;15(5–6):243–249
   PubMed Web of Science ®Google Scholar
• Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012;158(6):739–748
   PubMed Web of Science ®Google Scholar
• Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70(5):1970–1980
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311–5532
   PubMed Web of Science ®Google Scholar